JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Corvus Pharmaceuticals Inc

Închisă

7.16 -0.28

Rezumat

Modificarea prețului

24h

Curent

Minim

7.01

Maxim

7.35

Indicatori cheie

By Trading Economics

Venit

-23M

-8M

Marjă de profit

-13,764.773

Angajați

31

EBITDA

-360K

-10M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+94.99% upside

Dividende

By Dow Jones

Următoarele câștiguri

12 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

224M

557M

Deschiderea anterioară

7.44

Închiderea anterioară

7.16

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Corvus Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 oct. 2025, 20:49 UTC

Câștiguri

Correction to Thermo Fisher Article on Oct. 22

23 oct. 2025, 23:51 UTC

Market Talk

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 oct. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 oct. 2025, 23:49 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 oct. 2025, 23:37 UTC

Market Talk

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 oct. 2025, 22:58 UTC

Market Talk

Global Energy Roundup: Market Talk

23 oct. 2025, 22:57 UTC

Market Talk

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 oct. 2025, 22:49 UTC

Achiziții, Fuziuni, Preluări

How Trump Sparked a New Era of State Capitalism -2-

23 oct. 2025, 22:49 UTC

Achiziții, Fuziuni, Preluări

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 oct. 2025, 22:17 UTC

Câștiguri

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 oct. 2025, 21:41 UTC

Câștiguri

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 oct. 2025, 21:05 UTC

Câștiguri

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 oct. 2025, 20:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

23 oct. 2025, 20:50 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

23 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 oct. 2025, 20:35 UTC

Câștiguri

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 oct. 2025, 20:28 UTC

Câștiguri

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 oct. 2025, 20:15 UTC

Market Talk
Câștiguri

Global Commodities Roundup: Market Talk

23 oct. 2025, 20:10 UTC

Câștiguri

Newmont Mining 3Q Adj EPS $1.71

23 oct. 2025, 20:10 UTC

Câștiguri

Newmont Mining 3Q Sales $5.52B

23 oct. 2025, 20:10 UTC

Câștiguri

Newmont Mining 3Q EPS $1.67

23 oct. 2025, 20:09 UTC

Câștiguri

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 oct. 2025, 20:07 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

23 oct. 2025, 20:07 UTC

Market Talk
Câștiguri

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 oct. 2025, 20:07 UTC

Câștiguri

Blackstone Looks to IPOs for Investment Exits -- Update

23 oct. 2025, 20:05 UTC

Câștiguri

Intel 3Q Gross Margin 38.2% >INTC

23 oct. 2025, 20:04 UTC

Câștiguri

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 oct. 2025, 20:04 UTC

Câștiguri

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 oct. 2025, 20:04 UTC

Câștiguri

Intel: 4Q Guidance Excludes Altera >INTC

23 oct. 2025, 20:04 UTC

Câștiguri

Intel Sees 4Q Adj EPS 8c >INTC

Comparație

Modificare preț

Corvus Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

94.99% sus

Prognoză pe 12 luni

Medie 14 USD  94.99%

Maxim 16 USD

Minim 11 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCorvus Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

3 ratings

3

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

3.165 / 3.5827Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Weak Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat